The Annual General Meeting (the ”AGM”) on June 1, 2018 decided to adopt the balance sheet, income statement, consolidated income statement and consolidated balance sheet for 2017. Furthermore, it was decided that no dividend will be distributed and disposable profits as of 2017-12-31 are carried forward to future periods.
The AGM also decided to discharge the board members and the CEO from liability for 2017. The AGM approved the nominating committee’s proposal that the board shall consist of five board members without deputies.
The AGM decided that the remuneration to the chairman of the board shall amount to SEK 500,000 and that the remuneration to the other board members not employed by the company shall be SEK 200,000 each. No additional remuneration is proposed for committee work. The total remuneration to the board is hence amounted to SEK 1,100,000.
The AGM also decided that the remuneration to the auditor, as previous, will be on specified current account.
The AGM decided that the board until the end of the next Annual General Meeting will consist of the members Anders Wiklund, Kleanthis G. Xanthopoulos, Marios Fotiadis, Saeid Esmaeilzadeh and Anita Tollstadius. Anders Wiklund was re-elected chairman of the board.
KPMG AB was re-elected as the company’s auditor, with Duane Swanson as auditor in charge, until the end of the Annual General Meeting of 2019.
The AGM approved the proposed instructions for the nomination committee.
The AGM approved the board’s proposed remuneration guidelines for senior management.
The AGM approved the board’s proposals of a new incentive program for the employees of the company.
The AGM approved the board’s proposal to be authorized to increase share capital through the issue of new shares and/or convertibles.
Complete proposals regarding the AGM’s decisions are available on IRRAS AB:s website www.irras.com.
For more information, please contact:
CFO and Deputy CEO
+46 706 67 31 06
IRRAS AB (NASDAQ Stockholm: IRRAS) is a publicly-traded, commercial-stage medical technology company focused on developing and commercializing innovative solutions for brain surgery. The Company’s initial product, IRRAflow™, addresses the complications associated with the current treatment methods of intracranial bleeding with a dual lumen catheter that combines active irrigation with ongoing fluid drainage. Regularly during treatment, the catheter is automatically flushed to prevent common catheter occlusions from forming. Additionally, because IRRAflow is a completely closed system, it is designed to reduce the documented infection risk of these procedures.
With its unique product portfolio, protected by property patents and patent applications, IRRAS is well-positioned to establish a leadership position in the medical device market. IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
This document is considered information that IRRAS is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on June 1, 2018 at 22.00 p.m. (CET).
Press release (PDF)